AC Immune SA RSI
Quel est le RSI de AC Immune SA?
Le RSI de AC Immune SA est 38.74
Quelle est la définition de RSI?
L'indice de force relative (RSI 14) est un indicateur de dynamique qui compare l'ampleur des gains et des pertes sur une période donnée afin de mesurer la vitesse et l'évolution des mouvements de prix d'un titre.
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI des entreprises dans Health Care secteur sur NASDAQ par rapport à AC Immune SA
Que fait AC Immune SA?
ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor
Entreprises avec rsi similaire à AC Immune SA
- ECMOHO Ltd a RSI de 38.72
- People`s United Inc a RSI de 38.73
- Inventure Growth & Securities a RSI de 38.73
- GoHealth a RSI de 38.73
- Crescita Therapeutics a RSI de 38.73
- Novonix a RSI de 38.73
- AC Immune SA a RSI de 38.74
- CMC Metals a RSI de 38.75
- New Century Hong Kong a RSI de 38.75
- Sievi Capital Oyj a RSI de 38.75
- Discovery Inc a RSI de 38.75
- Landis+Gyr AG a RSI de 38.75
- Sang Hing Hldg (Intl) Ltd a RSI de 38.75